Efficacy and Safety of Regorafenib Monotherapy among Patients with Previously Treated Metastatic Colorectal Cancer in a Chinese Population: A Real-World Exploratory Study

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Bai M, Li ZG, Ba Y. Influence of KDR genetic variation on the efficacy and safety of patients with chemotherapy refractory metastatic CRC who received apatinib treatment. Int J Gen Med. 2021;14:1041–1055. doi:10.2147/ijgm.s300968
   PubMed Web of Science ®Google Scholar
• Ku G, Tan IB, Yau T, et al. Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012. Lancet Oncol. 2012;13(11):e470–481. doi:10.1016/s1470-2045(12)70424-2
   PubMed Web of Science ®Google Scholar
• Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, Phase 3 trial. Lancet Oncol. 2014;15(10):1065–1075. doi:10.1016/s1470-2045(14)70330-4
   PubMed Web of Science ®Google Scholar
• Papachristos A, Kemos P, Kalofonos H, Sivolapenko G. Correlation between bevacizumab exposure and survival in patients with metastatic colorectal cancer. Oncologist. 2020;25(10):853–858. doi:10.1634/theoncologist.2019-0835
   PubMed Web of Science ®Google Scholar
• Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized Phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26(12):2006–2012. doi:10.1200/jco.2007.14.9898
   PubMed Web of Science ®Google Scholar
• Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16(5):499–508. doi:10.1016/s1470-2045(15)70127-0
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO Randomized Clinical Trial. JAMA. 2018;319(24):2486–2496. doi:10.1001/jama.2018.7855
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(6):619–629. doi:10.1016/s1470-2045(15)70156-7
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245–255. doi:10.1002/ijc.25864
   PubMed Web of Science ®Google Scholar
• Jing Z, Rui Z, Binglan Z. A comparison of regorafenib and fruquintinib for metastatic colorectal cancer: a systematic review and network meta-analysis. J Cancer Res Clin Oncol. 2019;145(9):2313–2323. doi:10.1007/s00432-019-02964-6
   PubMed Web of Science ®Google Scholar
• Wang F, Yuan X, Jia J, et al. Apatinib monotherapy for chemotherapy-refractory metastatic colorectal cancer: a Multi-centre, Single-Arm, Prospective Study. Sci Rep. 2020;10(1):6058. doi:10.1038/s41598-020-62961-5
   PubMed Web of Science ®Google Scholar
• Liu X, Qin S, Wang Z, et al. Correction to: early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol. 2018;11(1):5. doi:10.1186/s13045-017-0545-5
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Kawakami K, Yokokawa T, et al. Association of hand-foot skin reaction with regorafenib efficacy in the treatment of metastatic colorectal cancer. Oncology. 2019;96(4):200–206. doi:10.1159/000495989
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Miller TP, Fisher BT, Getz KD, et al. Unintended consequences of evolution of the common terminology criteria for adverse events. Pediatr Blood Cancer. 2019;66(7):e27747. doi:10.1002/pbc.27747
   PubMed Web of Science ®Google Scholar
• Cheng JD, Chai LX, Zhao ZP, Hao YY, Li S. Efficacy and safety of anlotinib for patients with advanced NSCLC who progressed after standard regimens and the preliminary analysis of an efficacy predictor. Cancer Manag Res. 2020;12:5641–5650. doi:10.2147/cmar.s253366
   PubMed Web of Science ®Google Scholar
• Røed Skårderud M, Polk A, Kjeldgaard Vistisen K, Larsen FO, Nielsen DL. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a systematic review. Cancer Treat Rev. 2018;62:61–73. doi:10.1016/j.ctrv.2017.10.011
   PubMed Web of Science ®Google Scholar
• Suenaga M, Schirripa M, Cao S, et al. Gene polymorphisms in the CCL5/CCR5 pathway as a genetic biomarker for outcome and hand-foot skin reaction in metastatic colorectal cancer patients treated with regorafenib. Clin Colorectal Cancer. 2018;17(2):e395–e414. doi:10.1016/j.clcc.2018.02.010
   PubMed Web of Science ®Google Scholar
• Aljubran A, Elshenawy MA, Kandil M, et al. Efficacy of regorafenib in metastatic colorectal cancer: a Multi-institutional Retrospective Study. Clin Med Insights Oncol. 2019;13:1179554918825447. doi:10.1177/1179554918825447
   Web of Science ®Google Scholar
• Patel A, Sharma MC, Mallick S, Patel M, Bakhshi S. Poor performance status, urban residence and female sex predict inferior survival in pediatric advanced stage mature B-NHL in an Indian tertiary care center. Pediatr Hematol Oncol. 2018;35(1):23–32. doi:10.1080/08880018.2018.1424279
   PubMed Web of Science ®Google Scholar
• Kopeckova K, Buchler T, Bortlicek Z, et al. Regorafenib in the real-life clinical practice: data from the Czech Registry. Target Oncol. 2017;12(1):89–95. doi:10.1007/s11523-016-0458-1
   PubMed Web of Science ®Google Scholar
• Ducreux M, Petersen LN, Öhler L, et al. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study. Eur J Cancer. 2019;123:146–154. doi:10.1016/j.ejca.2019.09.015
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Martinelli E, Cascinu S, et al. Regorafenib for Patients with metastatic colorectal cancer who progressed after standard therapy: results of the large, single-arm, open-label Phase IIIb CONSIGN Study. Oncologist. 2019;24(2):185–192. doi:10.1634/theoncologist.2018-0072
   PubMed Web of Science ®Google Scholar
• Mekenkamp LJ, Heesterbeek KJ, Koopman M, et al. Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer. 2012;48(4):501–509. doi:10.1016/j.ejca.2011.12.004
   PubMed Web of Science ®Google Scholar
• Luo C, Cen S, Ding G, Wu W. Mucinous colorectal adenocarcinoma: clinical pathology and treatment options. Cancer Commun (Lond). 2019;39(1):13. doi:10.1186/s40880-019-0361-0
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–312. doi:10.1016/s0140-6736(12)61900-x
   PubMed Web of Science ®Google Scholar
• Calcagno F, Lenoble S, Lakkis Z, et al. Efficacy, safety and cost of regorafenib in patients with metastatic colorectal cancer in French clinical practice. Clin Med Insights Oncol. 2016;10:59–66. doi:10.4137/cmo.s38335
   PubMedGoogle Scholar
• Franke AJ, Skelton WP, Starr JS, et al. Immunotherapy for colorectal cancer: a review of current and novel therapeutic approaches. J Natl Cancer Inst. 2019;111(11):1131–1141. doi:10.1093/jnci/djz093
   PubMedGoogle Scholar
• Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–375. doi:10.1038/s41575-019-0126-x
   PubMed Web of Science ®Google Scholar
• Rawla P, Barsouk A, Hadjinicolaou AV, Barsouk A. Immunotherapies and targeted therapies in the treatment of metastatic colorectal cancer. Med Sci (Basel). 2019;7(8):83. doi:10.3390/medsci7080083
   PubMedGoogle Scholar
• Song PF, Xu N, Li Q. Efficacy and safety of anlotinib for elderly patients with previously treated extensive-stage SCLC and the prognostic significance of common adverse reactions. Cancer Manag Res. 2020;12:11133–11143. doi:10.2147/cmar.s275624
   PubMed Web of Science ®Google Scholar
• Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol. 2007;8(1):15–27. doi:10.1007/s11864-007-0022-4
   PubMedGoogle Scholar
• Tang JR, Markham NE, Lin YJ, et al. Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol. 2004;287(2):L344–351. doi:10.1152/ajplung.00291.2003
   PubMed Web of Science ®Google Scholar
• Fischer A, Wu S, Ho AL, Lacouture ME. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs. 2013;31(3):787–797. doi:10.1007/s10637-013-9927-x
   PubMed Web of Science ®Google Scholar